Brutalist Biotech

• The next generation of pulsed field ablation takes the stage at HRS annual meeting (2d)
• ALX Oncology doubles down on lead CD47 inhibitor after asset fails two midstage cancer trials (2d)
• HHS reverses course, says long-running women’s health study will retain funding (2d)
• Study illustrates pros, cons in AI readings of 3D mammography scans (2d)
• M&A remains ‘top priority’ for Big Pharmas in the face of tariff threat (2d)
• FDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concerns (2d)
• Caribou cuts 32% of staff, further purges pipeline to focus on oncology CAR-T prospects (3d)
• Chutes & Ladders—Galapagos CEO eyes exit as spinout names leader (3d)
• Ex-FDA leader joins new initiative designed to fight ‘unfortunate reality’ of vaccine landscape (3d)
• Boston Scientific plans to make ground despite $200M in tariff headwinds (3d)

• Biohaven stock slides on withdrawal of European marketing application (2d)
• Gilead leans on HIV drugs as oncology sales slow (2d)
• Halozyme sues Merck; FDA blames cuts for Vanda delay (2d)
• Caribou, in reversal, scraps autoimmune cell therapy and cuts staff (2d)
• Bristol Myers says schizophrenia drug launch ‘off to a solid start’ (3d)
• Merck takes $200M tariff hit, trimming its gross profits (3d)
• Sanofi stays course amid tariff turmoil (3d)
• Versant startup Granite debuts with $100M and two immune drugs (3d)
• Etiome, a new Flagship startup, looks to catch disease before it strikes (3d)
• German antibody maker valued at $1.6B in blank-check merger (4d)

• J&J reports durability data for bladder cancer 'pretzel' drug (1d)
• Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more (1d)
• FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill (2d)
• AbbVie eyes $10B US expansion amid sector-specific tariff threat (2d)
• Amgen invests $900M to expand Ohio biomanufacturing (2d)
• Compounding pharmacies dealt blow in semaglutide shortage case (2d)
• RFK Jr. touts program testing ways to pay for sickle cell care (2d)
• Akeso reveals survival data for Keytruda-beating cancer drug (2d)
• ALX Oncology reports Phase 2 failures for CD47 drug combo with Keytruda (2d)
• Alis Biosciences to press struggling biotechs during downturn (2d)

• Caribou Changes Course Again, Lays Off 32% of Workforce (2d)
• Fact or Fiction? Unpacking FDA Commissioner Marty Makary’s First Interviews (2d)
• AbbVie Lambasts Trump’s Drug Pricing Proposal, Deflects Tariff Concerns (2d)
• Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis (2d)
• SpringWorks Surges on Potential $3.5B Merck KGaA Buyout (2d)
• Judge Rules Against Semaglutide Compounders After Shortage Ruled Over (2d)
• Gilead’s PrEP Launch Full Speed Ahead, Despite Macro Pressures on HIV Space (2d)
• Merck, Boehringer Ingelheim, More to Present Key Data at AACR ‘25 (2d)
• BMS Reports Mixed Earnings as Growth Portfolio Makes Up for Generic Pressure (3d)
• Tariff Uncertainty Reigns Over Q1 Earnings, With Merck Taking $200M Blow So Far (3d)

Bio IT World

• Advancing Precision Medicine with Ethical AI and Standardized Data (2d)
• Tech Veteran Chris Dwan Challenges Life Sciences to Build Infrastructure, Businesses Strategically (4d)
• AI in Drug Development: Promise and Pitfalls (5d)
• Insilico’s Alex Zhavoronkov Highlights Generative AI's Impact on Drug Discovery and Aging Research (1w)
• AI Continues to Make Strides on Therapeutics and Research Progress (2w)
• Derek Lowe on AI in Drug Discovery: Between Hype and Hope (2w)
• Large Language Model Predicts, as Well as Explains, Molecular Properties (2w)
• AI Struggles and Opportunities in Life Sciences and Healthcare (3w)
• Researchers Transform Gut Bacteria into ‘Little Pharmacists’ (3w)
• Bio-IT Community Honors New Products from Boulder BioComputing, Dantech Corp, The Hyve, Velsera (3w)

• U.S. health officials inject new uncertainty into approval process for Covid boosters (41m)
• ‘Fight for your science’: Researchers urged to speak out at AACR (2h)
• Taking science’s temperature at the annual AACR meeting (1d)
• STAT readers on the animal wellness industry, drug price floors, and more (1d)
• Rural health study is told it’s losing federal funds, and other major heart studies are worried (2d)
• Sutter Health will pay nearly $230 million to settle class-action antitrust case (2d)
• NIH announces six new acting institute directors, many of them filling posts of ousted predecessors (2d)
• Luigi Mangione pleads not guilty to federal murder charge in killing of UnitedHealthcare’s CEO (2d)
• Up and down the ladder: The latest comings and goings (2d)
• Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda (2d)

• NHS Wales Pilots Paige AI Tool to Triage Cancer Cases (3d)
• Novotech Report: Over 800 Global IPF Trials Since 2020, Led by Asia-Pacific (3d)
• Immunai and Parker Institute to Build Largest Single-Cell Dataset for Real-World Immunotherapy Research (3d)
• Potato Lands $4.5M to Automate Lab Work with AI and Robots (3d)
• Tempus, AstraZeneca, and Pathos Partner to Build Oncology Foundation Model Using Multimodal Data (4d)
• GeneDx to Acquire Fabric Genomics to Enable AI-Powered, Decentralized Genome Interpretation (2w)
• Elix and PRISM BioLab Partner to Tackle Hard-to-Drug Protein Targets with AI (2w)
• Netherlands Outlines 2040 Biotech Vision, Emphasizing Tools, Commercialization, and Regulatory Reform (2w)
• Sanger and PacBio Launch Long-Read Effort to Decode Immune Gene Activity (2w)
• Finalists Announced for $10M Coller Dolittle Challenge on AI-Powered Interspecies Communication (2w)

• The past, present, and future of genome sequencing (2d)
• AI in biotech today, and how it will impact the industry tomorrow (2d)
• 21 UK biotech companies you should know about (3d)
• The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval (4d)
• Tariffs and trade war: A guide for expanding biotech business internationally (5d)
• Tariffs and trade war: A guide for expanding biotech business internationally (5d)
• Seven biotechs to watch in the hepatitis B space (5d)
• Biomaterials in construction: meet the startups reinventing our buildings (1w)
• HIV innovation: Six companies developing new treatments in 2025 (2w)
• Beyond CRISPR: Brink Therapeutics raises $4 million with engineered recombinases (2w)

• StockWatch: Tools Giants Foresee Revenue Impacts from Tariffs, Job Cuts (3h)
• Navigating Biotech’s New Normal, AI to Engineer Cas9 Enzymes, and Sequencing Generations (2d)
• BioSkryb and Tecan Introduce Single-Cell Multiomics Workflow (2d)
• AACR 2025 Chairs Identify Themes and Highlights From the Conference (2d)
• Sugar Swap Leads to Sweet Spot in Creating “Super Stem Cells” (2d)
• New Podcast, The ImmunoVerse, Highlights Immunotherapy Research (3d)
• Blocking Erythropoietin Signaling Renders Mouse Liver Tumors Sensitive to Anti-PD-1 Therapy (3d)
• Blocking Erythropoietin Signaling in Mice Converts Liver Tumors into Immunotherapy Responders (3d)
• AACR 2025: Professional Awards Acknowledge Contributions to Cancer Research and Treatment (3d)
• Signal Alert: Startup Seeks Community Funders for AAV Immuno-Gene Therapy (3d)

• Healer, Mentor and Leader (5h)
• Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models (5h)
• FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors (1d)
• Crafting an Individual Treatment Plan for Patients With Prostate Cancer (1d)
• Commitment to Patients Is Driven by a Lasting Promise (2d)
• Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care (2d)
• New Options for ER+ Breast Cancer Spotlighted at Patient Event (2d)
• A Digital Detox for the Soul with Lynch Syndrome (2d)
• Decipher Prostate Test Now Available for Metastatic Prostate Cancer (2d)
• Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer (2d)

Contract Pharma*

• FDA Approves Akeso’s Penpulimab for Nasopharyngeal Carcinoma (2d)
• CPTx Appoints McDavid Stilwell as Chief Financial Officer (3d)
• BMS Pays Evotec $75M for Molecular Glue Research Progress (3d)
• Mosaic Therapeutics In-Licenses Oncology Programs from Astex (3d)
• CN Bio & Pharmaron Partner to Advance Organ-on-a-Chip Drug Discovery (3d)
• Hansa Biopharma Appoints New CEO (3d)
• Debiopharm & Oncodesign Partner on Cancer Imaging Tech (3d)
• Ferring Pharmaceuticals’ Drug Product Manufacturing Hub in NJ Approved by FDA (3d)
• Integer Announces CEO Succession Plan (3d)
• PCI Pharma Services to Acquire Ajinomoto Althea (3d)

• Acoramidis approved for heart condition treatment (2d)
• Genomics study launches to optimise childhood cancer care in Ireland (3d)
• UCL researchers launch congenital muscular dystrophy research programme (4d)
• Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine (5d)
• FDA approves Click’s digital therapeutic for episodic migraine (1w)
• Leqembi approved as first treatment to slow early Alzheimer’s progression (2w)
• Pepaxti shows effectiveness in heavily pretreated multiple myeloma patients (2w)
• New data reinforce daratumumab as standard of care for multiple myeloma (2w)
• Global data highlights effectiveness of romosozumab (2w)
• UK clinical trials regulations signed into law (2w)

• Bringing Patient Data to the Frontlines: Why Interoperability Must Include EMS (9h)
• Hospitals Are Freezing M&A Deals as Federal Policies Rattle Industry (9h)
• Novo Nordisk Notches a Court Win Against Wegovy and Ozempic Compounders (10h)
• The Silent Mental Health Crisis of Climate Change (10h)
• Orchestra BioMed’s Hypertension Device Wins FDA Breakthrough Designation (2d)
• CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies (2d)
• Agentic AI and the Architecture of Healthcare Transformation (2d)
• 5 Major Trends Emerging in Healthcare Benefits in 2025 (2d)
• Community-Driven Digital Solutions Can Transform Addiction Treatment and Ease the Burden on the Healthcare System (2d)
• Nourish Lands $70M to Fight Chronic Disease with Nutrition Care (3d)

• US halts funding for new COVID-19 vaccines (2d)
• OxyVinyls will contribute to the $600 million settlement in the East Palestine train derailment case (2d)
• Grove Biopharma launches to develop therapeutic protein-like polymers (2d)
• Periodic Graphics: Permanent magnets explained (2d)
• A new way to recycle waste silicones (2d)
• Nylon maker Ascend files for bankruptcy (3d)
• Dow plans deep cuts amid poor economy (3d)
• More hurt for European chemical firms (3d)
• How to read science news (3d)
• US rule targets federal workers who don't advance Trump's policies (3d)

The Pharma Letter*

• The week in pharma: action, reaction and insight – week to April 25 (12h)
• Amgen announces $900 million production investment (1d)
• MHRA nod for Bayer’s Beyonttra for ATTR-CM (1d)
• New medicines recommended for approval by CHMP in April 2025 (1d)
• AbbVie arrows upwards on upgraded earnings estimate (2d)
• New EC nod for J&J’s Tremfya (2d)
• Guardant Health and Pfizer team up (2d)
• LTZ bags $40 million as it sends first myeloid engager into clinic (2d)
• Industry-backed study highlights value of antibiotic R&D incentive (2d)
• Convatec to launch nitric oxide product as analysts highlight resilience (2d)

• SunRISe-1 Cohort 4: Promising TAR-200 Outcomes in Papillary NMIBC (3h)
• Bladder Cancer Takes Center Stage With Breakthrough Advancements at AUA 2025 (6h)
• KEYNOTE-689 Trial of Pembrolizumab Shows Promising EFS in LA-HNSCC (6h)
• Disitamab Vedotin Plus BCG Shows Promise in HER2-Expressing, High-Risk NMIBC (7h)
• Nogapendekin Alfa Inbakicept Impresses With Stable CR and Cystectomy-Avoidance Rate in BCG-Unresponsive Bladder Carcinoma (7h)
• The Targeted Pulse: AI Cancer Diagnosis, Breast Cancer Treatment Updates, and More (12h)
• High CR Rate with Cretostimogene for BCG-Failed Bladder Cancer (1d)
• TAR-200 Shows Durable Response in BCG-Unresponsive NMIBC: SunRISe-1 Cohort 2 (1d)
• Predicting Cretostimogene Grenadenorepvec Response With Urinary Genomics (1d)
• EVP With Consolidative Surgery Yields Promising Outcomes in Bladder Cancer (1d)

• Analyst predicts trouble ahead for GN: Trade war could derail transformation (2d)
• SSI Diagnostica increases US footprint with another acquisition (2d)
• More obesity companies want to compete on healthy weight loss and solving "ethical challenge" (2d)
• Bristol Myers Squibb fails in phase 3 trial of schizophrenia drug (2d)
• Good news for Novo in the US: Compounding pharmacies to stop sales of Wegovy and Ozempic copies (2d)
• Analyst predicts tablets will take a large share of the future obesity market: "The trend is definitely towards oral" (2d)
• MSD's Q1 figures show growth and reveal tariff impact (2d)
• Eli Lilly intensifies legal battle against copycat makers (2d)
• Fujifilm Diosynth Biotechnologies COO sees business advantage in geopolitical storm (2d)
• Sanofi's earnings soar on growing demand for blockbuster drug (2d)

• What's Going On In Water Droplets (2d)
• A New Glioblastoma Treatment (3d)
• Streptomycin For Metastatic Cancer (5d)
• The End of Disease (6d)
• You Can Probably Smell That Planet From Here (1w)
• Proton Pump Inhibitors Do More Than You Think (2w)
• Entropy, Enthalpy, and Hydrophobicity (2w)
• The Continuing Crisis, Part XII: Behold RFK Jr.'s FDA (2w)
• RNA Motifs Coming Into Focus (2w)
• Pharmaceutical Tariffs: The What and the How (3w)

• Ozempic patient blinded by NAION sues Novo Nordisk (2d)
• Akeso PD-1 inhibitor cleared as Keytruda challenger advances (2d)
• AbbVie files fast-acting Botox successor in US (2d)
• Granite Bio makes $100m debut, and other bio financings (2d)
• MSD has gauged its financial hit from Trump tariffs (2d)
• Merck puts a price on its SpringWorks takeover bid (2d)
• Irish study promises to revolutionise childhood cancer care (3d)
• Can Bioxodes end the dearth of haemorrhagic stroke drugs? (3d)
• Roche seeking talks with the US on tariff exemptions (3d)
• AstraZeneca joins Tempus, Pathos in cancer AI project (3d)

• Partners sign deal to build largest multimodal oncology foundation model (2d)
• This week in drug discovery (21-25 April) (2d)
• UMass joins Phase II trial for multiple sclerosis (2d)
• AACR data shows promise for patients with solid tumour types (2d)
• AI in drug discovery: Separating hype from reality, and what does it hold for CROs? (2d)
• Podcast: Where are scientists making waves in drug discovery? (3d)
• Where are scientists making waves in drug discovery? (3d)
• Roche reveals plans to invest $50 billion in the US (3d)
• Webinar: How can 3D cardiac microtissue models advance drug screening? (3d)
• Medicus extends Phase II study in nodular basal cell carcinoma (3d)

Google News Biotech

• Injectable Male Birth Control Effective for at Least 2 Years, Says Biotech Startup - Gizmodo (9h)
• Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks - WSJ (12h)
• Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks - Yahoo Finance (12h)
• Korea Herald Roundtable for Pharma & Biotech - The Korea Herald (18h)
• Rossari Biotech Releases Q4 & FY25 Earnings Presentation - MSN (21h)
• Breakthrough Cancer Vaccine Technology Reveals New Approach to Reprogram Tumor Environment - Stock Titan (1d)
• BioSpectrum Asia picks top 3 pharma & biotech exhibitors at ICPI Week 2025 - BioSpectrum Asia (1d)
• STAT readers on the animal wellness industry, drug price floors, and more - statnews.com (1d)
• Biotech company AMGEN launching a major expansion - nbc4i.com (1d)
• Biotech Company Reports Promising Neurological Treatment in Clinical Study - streetwisereports.com (2d)